Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment

Background:

• Colorectal cancers (CRCs) often show TGF-β pathway inactivation but paradoxically high TGF-β production.
• This suggests a complex role for TGF-β in CRC progression, particularly in metastasis.

Purpose of the Study:

• To investigate the prometastatic role of TGF-β in the tumor microenvironment of CRC.
• To identify the mechanisms by which TGF-β signaling in stromal cells promotes CRC metastasis and relapse.

Main Methods:

• Utilized mouse models of CRC and pharmacological inhibition of TGF-β receptor 1 (TGFBR1).
• Analyzed the role of cancer-associated fibroblasts (CAFs) and their secreted factors, specifically IL11.
• Investigated the downstream signaling pathways, including GP130/STAT3, in CRC cells.

Main Results:

• TGF-β activity on stromal cells enhances CRC cell organ colonization and metastasis.
• Pharmacological inhibition of TGFBR1 confers resilience to metastasis formation in mice.
• TGF-β-stimulated CAFs secrete IL11, which activates GP130/STAT3 signaling in CRC cells, conferring a survival advantage to metastatic cells.

Conclusions:

• A TGF-β-driven program in the tumor microenvironment promotes CRC metastasis and is associated with high relapse risk.
• Targeting this TGF-β stromal pathway, potentially via TGFBR1 inhibition or blocking IL11 signaling, offers a therapeutic strategy for CRC.
• Exploiting the dependency on this pathway could improve CRC diagnosis and treatment outcomes.